Skip to main content
logo
Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
19.49
+1.08 (5.87%)
At close: Jul 27, 2026, 4:00 PM EDT
19.60
+0.11 (0.56%)
After-hours: Jul 27, 2026, 7:34 PM EDT

Amylyx Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--87.37380.7922.230.29
Revenue Growth
---77.05%1612.94%7700.00%-56.15%
Gross Profit
---37.26355.3519.240.29
Operating Income
-78.88-153.29-314.7338.8-201.34-82.69
Net Income
-75.83-144.74-301.7449.27-198.38-87.93
Earnings Per Share
-1.50-1.53-4.430.70-3.39-13.35
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
279.77316.98176.5371.36346.9596.12
Total Debt
5.635.961.984.246.280
Net Cash (Debt)
274.14311.02174.52367.13340.6796.12
Net Cash Growth
35.25%78.22%-52.46%7.77%254.43%662.00%
Net Cash Per Share
2.723.292.565.255.8214.59

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-120.4-123.34-167.6511.92-179.87-74.8
Capital Expenditures
-0.13-0.14-0.16-1.24-2.53-0.35
Free Cash Flow
-120.53-123.48-167.810.68-182.4-75.15
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---42.65%93.32%86.54%100.00%
Operating Margin
---360.22%10.19%-905.72%-29013.30%
Pretax Margin
---345.81%14.26%-888.89%-30852.98%
Profit Margin
---345.36%12.94%-892.38%-30853.00%
FCF Margin
---192.06%2.80%-820.50%-26369.10%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
---21.03--
Forward PE
-6.876.8716.68--
P/FCF Ratio
---93.34--
PS Ratio
--2.972.62110.55-